Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:48 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
NCT02531633 · GlaxoSmithKline · PHASE3 · terminated · last registry update 2019-07-31 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “GSK decision to return rights to sirukumab to Janssen and discontinue sirukumab development in giant cell arteritis.” | – | Registry record, GlaxoSmithKline |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL6 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-06-30Phase 3 first posted: R-Pharm, Olokizumab 64 mg + Placebo (NCT04452474)
- 2020-05-08Phase 3 first posted: R-Pharm International, LLC, RPH-104 80 mg + Olokizumab 64 mg (NCT04380519)
- 2020-04-01Phase 3 first posted: University Hospital, Ghent, Anakinra + Siltuximab (NCT04330638)
- 2020-01-27Results posted on the registry: Janssen Research & Development, LLC, Siltuximab + Placebo (NCT01484275)
- 2019-06-11Results posted on the registry: Janssen Research & Development, LLC, Sirukumab 50 mg + Placebo (NCT02473289)
- 2019-05-06Results posted on the registry: Janssen Research & Development, LLC, Sirukumab 100 mg + Sirukumab 50 mg (NCT01856309)
- 2018-11-19Phase 3 first posted: CSL Behring, Clazakizumab + Physiologic saline solution (NCT03744910)
- 2018-10-09Results posted on the registry: Carla Greenbaum, MD, Siltuximab (NCT02641522)
- 2018-08-31Also stopped (withdrawn): GlaxoSmithKline, Sirukumab + Placebo (NCT02794519)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision